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Introduction 
 Since 1964, cigarette smoking and tobacco smoke pollution have caused the premature 
deaths of an estimated 14 million Americans in addition to substantially more around the world, 
making the dependence on nicotine consumption a very important matter of public health 
(Giovino 2007). It is estimated that tobacco use is responsible for almost 20 percent of all 
premature deaths in developed countries, making it the single largest cause of premature death 
worldwide (Dani & Heinemann 1996). Lung cancer is the leading cause of death among 
smokers, but other major risks associated with smoking include other forms of cancer, heart 
disease, other cardiovascular diseases, chronic respiratory diseases, pregnancy complications, 
and respiratory diseases in children due to second-hand smoking. Although per capita American 
tobacco consumption has declined significantly since the 1950s, as of 2005 one in five 
Americans still classified themselves as smokers (Giovino 2007). Despite a wide variety of 
current treatments for smoking cessation including nicotine patches, nicotine gum, nicotine 
sprays, and smokeless cigarettes, nicotine addiction remains one the most difficult drug 
addictions to treat. Only three to five percent of cigarette smokers who attempt to quit are able to 
remain abstinent for six to twelve months (Hughes et al 2004). Most smokers fails in their 
attempts to quit smoking within eight days, and it takes the average smoker numerous attempts to 
successfully quit smoking, if he or she ever succeeds in quitting at all (Hughes et al 2004).  
Neurological Basis for Nicotine Addiction 
 The mechanisms underlying the development of addiction are complex and include many 
neurotransmitter interactions involved in pleasure, motivation, and learning. Principal among 
these is the dopamine circuit with projections from the ventral tegmental area in the midbrain to 
the nucleus accumbens in the forebrain, often called the reward pathway (Cami & Farre 2003). 
Although the process is not completely understood, it is believed that nicotine addiction is 
mediated by the binding of nicotine molecules with nicotinic acetylcholine receptors on 
dopamine neurons in the ventral tegmental area. The binding of nicotine with these receptors, 
which are the main binding sites for nicotine in the body and are responsible for the regulation of 
a wide variety of bodily functions, leads to the downstream release of excess dopamine levels in 
the nucleus accumbens (Rice & Cragg 2004). In addition to this release of dopamine that is 
primarily responsible for the development of nicotine addiction, nicotinic acetylcholine receptor 
activation exhibits its many other effects on the body through excitatory postsynaptic responses 
at glutamate, GABA, and serotonin terminals (Dani 2001). The release of these other 
neurotransmitters occurs through a complex network of interacting neurotransmitter pathways, 
but the specific details of these pathways are not well understood (Levin et. al. 2008). 
Elucidating a better understanding of these neurotransmitter interactions has the potential to 
result in novel approaches for treating nicotine addiction.  
Histamine Antagonism and Pyrilamine 
In 1995, a serendipitous observation led to the discovery that the antipsychotic clozapine 
significantly reduced smoking in patients with schizophrenia (McEvoy et. al. 1995). Subsequent 
studies have found that, in normally functioning rats, moderate doses of clozapine exerts these 
effects by impairing working memory and blocking nicotine-induced memory and attentional 
improvement (Levin et. al. 2007). Clozapine is a complex drug that acts as an antagonist at a 
variety of neurotransmitter receptors such as those for dopamine, serotonin, norepinephrine, and 
histamine.  
Following these discoveries, multiple studies have been conducted in an effort to better 
elucidate by which of these neurological pathways clozapine exerts its smoking-reducing effects. 
Pyrilamine, an H1 histamine antagonist that is often used as an antihistaminic agent in over-the-
counter cold medication, recently has been shown to decrease nicotine self-administration in rats 
(Levin et. al. 2011). Although pyrilamine significantly reduces nicotine self-administration 
independently, it does not completely counteract the neural actions that underlie continued 
nicotine consumption, nor does it halt nicotine self-administration entirely. A combination 
therapy including drugs targeting other neurotransmitters may result in more beneficial 
interactions in the reward pathway, which could lead to greater and more significant reductions 
in nicotine self-administration. A discovery of such interactions in combination therapy may lead 
to novel treatments for nicotine addiction and smoking cessation.  
Serotonin Agonism and Lorcaserin  
 Lorcaserin, a selective 5-HT2C receptor agonist currently approved in the United States as 
a weight loss drug, also recently has been shown to decrease nicotine self-administration in rats 
(Higgins et. al. 2012) and attenuate other drug addictions in humans (Cunningham et. al. 2011). 
Bubar and Cunningham identify the role of 5-HT2C receptor activation in decreasing dopamine 
release as the principal mechanism by which lorcaserin and similar serotonin agonists reduce the 
reinforcing behavior critical in drug addiction (2006). Since serotonin plays a significant role in 
the reward pathway and lorcaserin has previously been shown to decrease nicotine 
administration independently, there is reason to believe that a combination therapy including 
drugs targeting other neurotransmitters may result in greater attenuation of nicotine self-
administration.  
Glutamate Antagonism and Dextromethorphan 
 Dextromethorphan, an over-the-counter antitussive agent that can act as a dissociative 
hallucinogen at high doses, has recently been shown to reduce nicotine self-administration in rats 
(Glick et. al. 2001). Dextromethorphan and its principle metabolite dextrorphan have many 
mechanisms of action. It may act as a nonselective serotonin reuptake inhibitor, sigma-1 receptor 
antagonist, and NMDA glutamate receptor antagonist. It has also been shown that 
dextromethorphan can act as a noncompetitive alpha-3 beta-4 nicotinic antagonist. (Hernandez et 
al 2000). This mechanism of action, in combination with the NMDA glutamate antagonism that 
suppresses reinforcing drug effects, is believed to be responsible for dextromethorphan’s ability 
to reduce nicotine self-administration.  
Potential Interactions of Dextromethorphan, Pyrilamine, and Lorcaserin 
 In this study, we test two drug combinations, 1) dextromethorphan and pyrilamine and 2) 
dextromethorphan and lorcaserin, in a rat model of nicotine addiction to determine if any 
significant neurotransmitter interactions between the two drugs exist. I believe that by combining 
two drugs targeting neurotransmitter receptors involved in the reward pathway, additive or 
synergistic effects may result in more significant levels of nicotine self-administration reduction 
compared to the administration of either drug independently, and potentially elucidate more 
details about the reward pathway.  
 In this study, we tested combinations of placebo, low, and high doses of 1) 
dextromethorphan and pyrilamine and 2) dextromethorphan and lorcaserin in rats to determine 
interaction effects in the following: 
 1) Nicotine self-administration as a model of nicotine addiction. 
 2) Locomotor activity as a measure of drug sedating and stimulating effects.  
3) Food pellet self-administration as a measure of drug effects on appetite and as a 
secondary measure of drug sedating and stimulating effects.  
While effects on nicotine self-administration are the primary concern for this study, effects on 
locomotor activity and food pellet self-administration are important control measures to ensure 
that reduction in nicotine self-administration is not a result of general sedation caused by one or 
both drugs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methods 
Animal Subjects 
 Young adult female rats were used for this study. Each rat used for this study was housed 
in a separate, properly bedded chamber in standard laboratory conditions approved by Duke 
University. Care was taken to transport the subjects through the laboratory with minimal stress. 
To ensure that rats were awake and in an active phase during experimental sessions, the housing 
room was kept in a reverse day/night cycle. Rats were consistently fed following experimental 
sessions and were given constant access to water through standard cage bottles or through 
automatic delivery lines in housing room racks. The rats were housed and cared for in conditions 
in accordance with all university, state, and federal regulation.  
Locomotor Activity 
 Locomotor activity of the subjects was observed using a Figure-8 maze, which was first 
demonstrated as a measure of locomotor activity by Norton et. al. (1975). As described in 
Ruppert et. al. (1985), this maze is a continuous enclosed alley (10 cm by 10 cm) in the shape of 
a Figure-8 (70 cm long and 42 cm wide with a 21 cm by 16 cm central arena) with two blind 
alleys extending 20 cm from either side. Eight infrared photobeams crossing the maze alleys are 
used to measure locomotor activity, one located on each of the two blind alleys and three on each 
of two loops of the Figure-8. Activity was determined based on the number of breaks in the 
photobeams over one hour, and trends in locomotor activity were analyzed to test for potential 
locomotor effects of the drugs dextromethorphan, pyrilamine, and lorcaserin (Timofeeva et al 
2008). Following four days of acclimation, rats were tested once for baseline locomotor activity 
without any drug injections prior to entering the maze. Over the next nine days, rats were tested 
with each combination of dextromethorphan (0, 10, 30 mg/kg) and pyrilamine (0, 13.3, 40 
mg/kg) or dextromethorphan (0, 10, 30 mg/kg) and lorcaserin (0, 0.625, 1.25 mg/kg), injected 10 
minutes prior in randomized chronological order.   
 
Figure 1: Figure-8 maze. The location of photocells (n=8) that detect motor activity is indicated 
by dark circles. (Reprinted from Ruppert et al 1985.) 
 
Subject Training  
 Prior to jugular catheterization surgery and nicotine self-administration sessions, rats 
must be trained to use the lever-press self-administration chambers purchased from MED 
Associates, Inc. Rats are placed in separate, dual operant chambers, having been in the absence 
of food for at least twelve hours. These chambers have one active and one inactive lever. The 
active lever is vertically paired with a cue light which illuminates when a food pellet is available. 
When the lever is pressed, a food pellet is delivered via a feeding tray, a .5s feedback tone is 
sounded, and the light goes out until another food pellet is available via lever press. The inactive 
lever does not have an illuminated cue light, and does not have any effect if pressed. Prior to 
training sessions, rats are placed in chambers for two overnight sessions, during which the rats 
are periodically delivered food pellets paired with illumination of the cue light until the rat learns 
to associate the illuminated lever with food pellet delivery. A rat passes an overnight session 
when it successfully presses the active lever 100 times. Following overnight sessions, the rat 
must self-administer at least 50 food pellets during three 30-minute pellet sessions (P1-P3) in the 
absence of the overnight, automatic pellet delivery to be considered successfully trained.  
Food Self-Administration  
 After the completion of locomotor activity sessions and pellet session training, rats 
continued with 30-minute food pellet self-administration chamber sessions in the presence of 
dextromethorphan and pyrilamine or dextromethorphan and lorcaserin to determine potential 
effect and interactions of these drugs on appetite and food self-administration at various doses. 
Over nine days, rats were given each combination of dextromethorphan (0, 10, 30 mg/kg) and 
pyrilamine (0, 13.3, 40 mg/kg) or dextromethorphan (0, 10, 30 mg/kg) and lorcaserin (0, 0.625, 
1.25 mg/kg) injected 10 minutes prior to pellet sessions in randomized chronological order.   
Preparation of Nicotine Solution  
 During self-administration, nicotine is administered to rats from lines attached through 
delivery ports into silicone-rubber catheter tubing implanted into the jugular vein. Solutions of 
0.03mg/kg nicotine bitartrate are prepared with appropriate masses of nicotine salt. Using 
contaminate-free glassware, the nicotine salt is dissolved in sterile saline and adjusted to a 
standard pH between 7.0 and 7.20 using varying molar concentrations of HCl and NaOH in 
saline. After being adjusted to a pH appropriate for intravenous infusion, the nicotine solution is 
filtered through a Nalgene filter to ensure proper sterilization. These solutions are stored in 
conical tubes covered in aluminum foil to ensure limited exposure to light. Between sessions 
nicotine solutions are refrigerated for no longer than two weeks before replacement.  
Jugular Catheterization Surgery  
Following successful completion of overnight and pellet training sessions, jugular 
catheterization surgery is performed in a sterile, aseptic environment. In preparation for surgery, 
a general anesthesia mix of the drugs medetomidine and ketamine is delivered via injection. The 
rat is then shaved and prepared for surgery. Following incision and separation of tissue, the 
jugular vein is tied off at the distal end of the cannula insertion area.  The catheter is inserted into 
the jugular vein just anterior to the heart and secured using cyanoacrylate adhesive. The external 
section of the catheter is sutured to the deep muscle and exits the body on the dorsal side of the 
rat just posterior to the scapulae. The catheter is held in place by a plastic delivery port and 
rubber underarm bands. The catheter is flushed with the anticoagulant heparin in sterile saline 
and the antibiotic gentamicin to prevent coagulation and infection following surgery.  
Nicotine Self-Administration Procedure 
 Following jugular catheterization, rats transition from self-administration of food pellets 
to nicotine by a similar mechanism. The same delivery chamber is used, and the lever that 
previously administered a food pellet when pressed now delivers a 0.03 mg/kg/infusion does of 
nicotine solution via the delivery line and catheter. As before, the opposing lever has no effect. 
Following each lever press and nicotine delivery, the cue light turns off for one minute, the house 
light turns on, and the lever is inactivated until the cue light illuminates again.  
Experimental Design 
 The rats are first exposed to five baseline nicotine self-administration sessions in the 
absence of dextromethorphan, pyrilamine, or lorcaserin. Before nicotine self-administration 
sessions, catheters are flushed with 0.3 ml of a 100units/ml heparinized saline solution. These 
sessions last for 45 minutes, and responses are measured using MED-PC software. The software 
measures correct and incorrect lever presses, total nicotine infusion, and 15-minute interval 
counts for nicotine infusion. Following sessions, nicotine is drawn out of the delivery port and 
replaced with 0.3 ml of a saline solution containing 8mg/ml of the antibiotic gentamicin and 
500units/ml of heparin. After the completion of nicotine-only baseline sessions, each dose 
combination of dextromethorphan (0, 3.3, 10 mg/kg) and pyrilamine (0, 4.43, 13.3 mg/kg) or 
dextromethorphan (0, 3.3, 10 mg/kg) and lorcaserin (0, 0.3125, 0.625 mg/kg) is administered via 
sub dermal injection 10 minutes prior to sessions using a repeat counterbalance format discussed 
below. As explained in the Results, following the results of the locomotor activity and pellet 
sessions, the dose ranges of the drugs for the nicotine self-administration trials were reduced.  
Repeated Measures Counterbalanced Design 
The repeated measures counterbalanced design was used to reduce the possibility that the 
order of dosage administration or other factors could impact the results. In this design, each 
subject receives each of the nine dose combinations twice over a four-week period, with the 
order of dose combinations being administered varying across the subject pool. This way, every 
subject participates in every condition but the orders of doses are different and each subject can 
serve as its own control.  
Data Analysis 
 Analysis of variance for repeated measures was conducted on the data and p<0.05 was 
considered the threshold for statistical significance.  
 
 
 
 
 
Results 
Single Drug Effects on Locomotor Activity  
Independently, all three drugs significantly decreased locomotor activity in a dose-
dependent manner when administered ten minutes prior to locomotor activity session. The higher 
30 mg/kg dose of dextromethorphan resulted in a significant decrease in locomotor activity 
relative to saline injection, while the lower 10 mg/kg dose did not result in a significant decrease 
(Fig. 2a). Both the higher 40 mg/kg dose and the lower 13.3 mg/kg dose of pyrilamine resulted in 
a significant decrease in locomotor activity relative to saline injection (Fig. 2b). Both the higher 
1.25 mg/kg dose and the lower 0.625 mg/kg dose of pyrilamine resulted in a significant decrease 
in locomotor activity relative to saline injection (Fig. 2c). 
Drug Interactions in Locomotor Activity 
 Significant interactions were observed with both drug combinations in locomotor activity 
trials. In the dextromethorphan-pyrilamine study, treatment with the lower 13.3 mg/kg dose of 
pyrilamine significantly interacted with both the lower 10 mg/kg dose and the higher 30 mg/kg 
dose of dextromethorphan in reducing locomotor activity by a greater margin than either dose 
alone (Fig. 3a). Treatment with the higher 40 mg/kg dose of pyrilamine also significantly 
interacted with the lower 10 mg/kg dose of dextromethorphan in decreasing locomotor activity. 
Treatment with the higher 40 mg/kg dose of pyrilamine appeared to interact with the higher 30 
mg/kg dose of dextromethorphan to increase locomotor activity contrary to the observed trends; 
however, these results are not significant.  In the dextromethorphan-lorcaserin study, treatment 
with the higher 1.25 mg/kg dose of lorcaserin significantly interacted with the higher 30 mg/kg 
dose of dextromethorphan in reducing locomotor activity by a greater margin than either dose 
alone (Fig. 3b). Both doses of lorcaserin appeared to reduce locomotor activity with 
dextromethorphan in a dose-dependent manner, but these results were not significant.  
Single Drug Effects on Food Self-Administration  
Following the general trend observed with locomotor activity, all three drugs 
significantly decreased food pellet self-administration independently in a dose-dependent 
manner. The higher 30 mg/kg dose of dextromethorphan significantly decreased food self-
administration relative to saline injection, while the lower 10 mg/kg dose did not (Fig. 4a). Both 
the higher 40 mg/kg dose and the lower 13.3 mg/kg dose of pyrilamine resulted in a significant 
decrease in food self-administration relative to saline injection (Fig. 4b). Both the higher 1.25 
mg/kg dose and the lower 0.625 mg/kg dose of lorcaserin resulted in a significant decrease in 
food self-administration relative to saline injection (Fig. 4c). 
Drug Interactions in Food Self-Administration  
 Significant interactions were only observed between dextromethorphan and pyrilamine in 
food pellet self-administration trials. Treatment with the lower 13.3 mg/kg dose of pyrilamine 
significantly interacted with both the lower 10 mg/kg and the higher 30 mg/kg doses of 
dextromethorphan in reducing food self-administration by a greater margin than either dose 
alone (Fig. 5a). Treatment with the higher 40 mg/kg dose of pyrilamine also significantly 
interacted with both the lower 10 mg/kg and the higher 30 mg/kg doses of dextromethorphan in 
reducing food self-administration.  No significant interactions were observed between 
dextromethorphan and lorcaserin in food self-administration (Fig. 5b). Treatment with the lower 
0.625 mg/kg dose of lorcaserin did appear to interact with both doses of dextromethorphan, but 
these results were not significant. 
 The low activity, or high sedation levels, observed with the high doses of 
dextromethorphan (30 mg/kg), pyrilamine (40 mg/kg), and lorcaserin (1.25 mg/kg) in the 
locomotor activity sessions and pellet sessions necessitated a decrease in the dose range used for 
nicotine self-administration. Following the locomotor activity and food pellet self-administration 
trials, the dose ranges were adjusted such that the old low dose became the new high dose for 
dextromethorphan (new range: 0, 3.3, 10 mg/kg), pyrilamine (new range: 0, 4.43, 13.3 mg/kg), 
and lorcaserin (new range: 0, 0.3125, 0.625 mg/kg).  
Single Drug Effects on Nicotine Self-Administration 
 In the dextromethorphan-pyrilamine study treatment with dextromethorphan ten minutes 
prior to nicotine self-administration sessions decreased nicotine self-administration in a dose-
dependent manner; however, these results were not significant (Fig. 6a). In the 
dextromethorphan-lorcaserin study, however, treatment with dextromethorphan was shown to 
significantly decrease nicotine self-administration in a dose-dependent manner, as expected (Fig. 
6b). In this study, both the lower 3.3 mg/kg dose and the higher 10 mg/kg dextromethorphan 
doses resulted in a significant decrease in nicotine self-administration relative to saline injection. 
As expected, treatment with both pyrilamine and lorcaserin ten minutes prior to nicotine self-
administration sessions significantly decreased nicotine self-administration independently in a 
dose-dependent manner. The higher 13.3 mg/kg dose of pyrilamine significantly decreased 
nicotine self-administration relative to saline injection, while the lower 4.43 mg/kg dose did not 
(Fig. 6c). The higher 0.625 mg/kg dose of lorcaserin did result in a significant decrease in 
nicotine self-administration relative to saline injection, while the lower 0.3125 mg/kg dose did 
not (Fig. 6d). 
 
Drug Interactions in Nicotine Self-Administration 
 Significant interactions in nicotine self-administration were only observed between 
dextromethorphan and lorcaserin. No significant interactions between dextromethorphan and 
pyrilamine were observed in the nicotine self-administration trials (Fig. 7a).  Treatment with the 
higher 0.625 mg/kg dose of lorcaserin significantly interacted with the lower 3.3 mg/kg dose of 
dextromethorphan in reducing nicotine self-administration by a greater margin than either dose 
alone. Treatment with the lower 0.3125 mg/kg dose of lorcaserin also significantly interacted 
with the higher 10 mg/kg dose of dextromethorphan in reducing nicotine self-administration 
(Fig. 7b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 
 
A)            B) 
 
C) 
 
 
Figure 2: Single Drug Effects on Locomotor Activity  
Average interval count refers to the average number of photobeam breaks per 5-minute time 
interval with each dose combination. A) In the dextromethorphan-pyrilamine study, treatment 
with dextromethorphan significantly decreased locomotor activity in a dose-dependent manner 
(F(2,30)=10.268, p<0.0005, n=15). The high dose of dextromethorphan did result in a significant 
decrease in locomotor activity relative to saline injection (F(1,30)=20.118, p<0.005, n=15). The 
low dose did not significantly decrease locomotor activity relative to saline injection 
(F(1,30)=2.838, p>0.1, n=15). Identical trends for effects of dextromethorphan alone on 
locomotor activity were observed in the dextromethorphan-lorcaserin study.  B) Treatment with 
pyrilamine significantly decreased locomotor activity in a dose-dependent manner 
(F(2,30)=15.247, p<0.0005, n=15). Both the high and low doses of pyrilamine resulted in a 
significant decrease in locomotor activity relative to saline injection (High dose: F(1,30)=26.481, 
p<0.005, n=15) (Low dose: F(1,30)=18.559, p<0.005, n=15). C) Treatment with lorcaserin did 
significantly decrease locomotor activity in a dose-dependent manner (F(2,30)=62.315, 
p<0.0001, n=15). Both the high and low doses of lorcaserin resulted in a significant decrease in 
locomotor activity relative to saline injection (High dose: F(1,30)= 50.97, p<0.0005, n=15) (Low 
dose: F(1,30)= 7.43, p<0.01, n=15). 
A) 
 
B) 
 
 
Figure 3: Drug Interactions in Locomotor Activity 
Average interval count refers to the average number of photobeam breaks per 5-minute time 
interval with each dose combination. A) Treatment with the low dose of pyrilamine did 
significantly interact with both the low and high dose of dextromethorphan, resulting in greater 
reductions in locomotor activity than with either dose alone (Low dose: F(1,30)=17.620, 
p<0.005, n=15) (High dose: F(1,30)=24.553, p<0.005, n=15). Treatment with the high dose of 
pyrilamine resulted in significant interactions with the low dose of dextromethorphan 
(F(1,30)=4.233, p<0.05, n=15). Treatment with the high dose of pyrilamine appears to interact 
with the high dose of dextromethorphan to increase locomotor activity, however these results are 
not significant (F(1,30)=2.163, p>0.1, n=15).  B) Treatment with the low dose of lorcaserin 
appears interact with the high dose of dextromethorphan, but these results are not significant. 
Treatment with the high dose of lorcaserin resulted in significant interactions with the high dose 
of dextromethorphan (F(1,30)= 7.42, p<0.01, n=15). Both doses of lorcaserin appeared to reduce 
locomotor activity with dextromethorphan in a dose-dependent manner, however these results 
are not significant (F(4,60)=0.224, p>0.5, n=15). 
A)          B) 
 
C) 
 
 
Figure 4: Single Drug Effects on Appetite and Food Self-Administration  
Average pellets per session refer to the average number of food pellets delivered per 30-minute 
self-administration session with each dose combination. A) In the dextromethorphan-pyrilamine 
study, treatment with dextromethorphan significantly decreased food self-administration in a 
dose-dependent manner (F(2,22)=58.094, p<0.0005, n=11). The high dose of dextromethorphan 
significantly decreased food self-administration relative to saline injection (F(1,22)=8.287, 
p<0.01, n=11). The low dose did not significantly decrease food self-administration relative to 
saline injection (F(1,22)=0.450, p>0.5, n=11). Identical trends for effects of dextromethorphan 
alone on food self-administration were observed in the dextromethorphan-lorcaserin study.  B) 
Treatment with pyrilamine did significantly decrease food self-administration in a dose-
dependent manner (F(2,22)=58.094, p<0.0005, n=11). Both the high and low doses of pyrilamine 
resulted in a significant decrease in food self-administration relative to saline injection (High 
dose: F(1,22)=77.425, p<0.0005, n=11) (Low dose: F(1,22)=10.677, p<0.005, n=11). C) 
Treatment with lorcaserin did significantly decrease food self-administration in a dose-dependent 
manner (F(2,30)=42.889, p<0.0001, n=15). Both the high and low doses of lorcaserin resulted in 
a significant decrease in food self-administration relative to saline injection (High dose: 
F(1,30)=79.192, p<0.0001, n=15) (Low dose: F(1,30)=4.959, p<0.05, n=15). 
 
 
 A) 
 
B) 
 
 
Figure 5: Drug Interactions on Food Self-Administration  
Average pellets per session refer to the average number of food pellets delivered per 30-minute 
self-administration session with each dose combination. A) Treatment with the low dose of 
pyrilamine did have significant interactions with both the low and high doses of 
dextromethorphan, resulting in greater reductions in food self-administration than with either 
dose alone (Low dose: F(1,22)=34.166, p<0.0005, n=11) (High dose: F(1,22)=90.042, p<0.0005, 
n=11). Treatment with the high dose of pyrilamine also had significant interactions with both the 
low and high doses of dextromethorphan (Low dose: F(1,22)=29.363, p<0.0005, n=11) (High 
dose: F(1,22)=43.448, p<0.0005, n=11). B) No significant interactions were observed between 
dextromethorphan and lorcaserin in food self-administration. Dextromethorphan and lorcaserin 
did not interact in a dose-dependent manner (F(4,60)=0.895, p>0.1, n=15). 
A)          B) 
 
C)           D) 
 
 
Figure 6: Single Drug Effects on Nicotine Self-Administration 
Average infusions per session refer to the average number of nicotine infusions delivered per 1-
hour self-administration session with each dose combination. A) In the dextromethorphan-
pyrilamine study, treatment with dextromethorphan alone was not shown to significantly 
decrease nicotine self-administration in a dose-dependent manner (F(2,22)=2.842, p>0.05, 
n=11). B) In the dextromethorphan-lorcaserin study, treatment with dextromethorphan was 
shown to significantly decrease nicotine self-administration in a dose-dependent manner 
(F(2,28)=18.539, p<0.0001, n=14). Both the high and low doses resulted in a significant decrease 
in nicotine self-administration relative to saline injection (Low dose: F(1,28)=21.972, p<0.0001, 
n=14) (High dose: F(1,28)=32.601, p<0.0001, n=14). C) Treatment with pyrilamine significantly 
decreased nicotine self-administration in a dose-dependent manner (F(2,22)=12.605, p<0.001, 
n=11). The high dose of pyrilamine significantly decreased nicotine self-administration relative 
to saline injection (F(1,22)=22.608, p<0.0005, n=11). The low dose did not significantly 
decrease nicotine self-administration relative to saline injection (F(1,22)=0.961, p>0.1, n=11). D) 
Treatment with lorcaserin ten minutes prior to nicotine self-administration sessions significantly 
decreased nicotine self-administration in a dose-dependent manner (F(2,28)=4.143, p<0.05, 
n=14). The high dose of lorcaserin significantly decreased nicotine self-administration relative to 
saline injection (F(1,28)=8.029, p<0.01, n=14). The low dose did not significantly decrease 
nicotine self-administration relative to saline injection (F(1,28)=3.443, p>0.05, n=14). 
A) 
 
 
B) 
 
 
Figure 7: Dextromethorphan and Lorcaserin Interactions in Nicotine Self-Administration 
Average infusions per session refer to the average number of nicotine infusions delivered per 1-
hour self-administration session with each dose combination. A) No significant interactions were 
observed between dextromethorphan and pyrilamine that resulted in greater reductions in 
nicotine self-administration compared to either drug alone. B) Treatment with the high dose of 
lorcaserin significantly interacted with the low dose of dextromethorphan to reduce nicotine self-
administration by a greater margin than either dose alone (F(1,56)=5.764, p<0.05, n=14). 
Treatment with the low dose of lorcaserin also significantly interacted with the high dose of 
dextromethorphan (F(1,56)=14.198, p<0.0005, n=14). 
 
 
Discussion 
Locomotor Activity 
 The results of the locomotor activity trials  suggest that the 30 mg/kg dose of 
dextromethorphan, the 13.3 and 40 mg/kg doses of pyrilamine, and the 0.625 and 1.25 mg/kg 
doses of lorcaserin cause significantly reduced activity levels. Since potential sedating effects are 
considered problematic for a potential nicotine addiction treatment and should be avoided, the 
investigation of the effects of lower doses of these drugs on locomotor activity may be in order.  
Food Self-Administration  
 Increased appetite and weight gain are common side effects associated with most 
traditional smoking cessation therapies, and novel treatment options should look to mitigate 
these side effects. With this in mind, the significant decreases in food self-administration 
observed with dextromethorphan, pyrilamine, and lorcaserin and the interactions between 
dextromethorphan and pyrilamine are promising for a potential smoking cessation drug. More 
work should be done to determine if these effects on food self-administration attenuate with 
longer exposure.  
Dextromethorphan and Pyrilamine Interactions 
In the dextromethorphan-pyrilamine study, no significant interactions were observed 
between the two drugs in reducing nicotine self-administration. As has been demonstrated by our 
laboratory in previous studies, pyrilamine did significantly reduce nicotine self-administration in 
a dose-dependent manner when compared to saline injection (Levin et al 2011). The results of 
this study, however, do not demonstrate any statistically significant reduction in nicotine self-
administration with dextromethorphan at any dose, contrary to the results observed in Glick et. 
al. 2001. This may be the result of desensitization following administration of the higher 30 
mg/kg dose in locomotor and pellet sessions, and the subsequent reduction of the maximum dose 
to 10 mg/kg in nicotine sessions. It is also possible that the reductive effects of 
dextromethorphan on nicotine self-administration observed in the Glick study were the result of 
sedation, since no locomotor activity or comparable tests were performed. A study using a 
maximum dextromethorphan dose of 10 mg/kg for locomotor, pellet, and nicotine sessions 
should be conducted to determine if the 10mg/kg dose of dextromethorphan can be effective at 
reducing self-administration over a long time frame without causing sedative effects.  
Dextromethorphan and Lorcaserin Interactions  
In the dextromethorphan-lorcaserin study, however, dextromethorphan was observed to 
significantly reduce nicotine self-administration in a dose-dependent manner, in contrast to the 
results observed in the dextromethorphan-pyrilamine study but in accordance with the results 
seen in Glick et al 2001. This conflicting data suggests that the results observed in the 
dextromethorphan-pyrilamine study may be anomalous, and that perhaps co-administration with 
pyrilamine results in desensitization to the nicotine self-administration reduction generally 
caused by dextromethorphan. Further research is required to characterize this potential 
relationship between dextromethorphan and pyrilamine and confirm the attenuating effects of 
dextromethorphan on nicotine self-administration.  
Additionally, further inquiry into the use of dextromethorphan in other drug addiction 
treatments is warranted as previous studies have shown that dextromethorphan may be useful in 
the treatment of opioid and methamphetamine addiction (Glick et al 2001) and cocaine addiction 
(Pulvirenti et al 1997). It should be recognized, however, that dextromethorphan has the potential 
for recreational abuse as a dissociative hallucinogen. Any drug addiction treatment containing 
dextromethorphan should not simply substitute one addictive drug for another. Future studies 
should investigate if rats will self-administer dextromethorphan to evaluate its potential for 
addiction, and new applications for this drug should be carefully considered.  
The dextromethorphan-lorcaserin study also corroborates the results of Higgins et. al. in 
showing that lorcaserin reduces nicotine self-administration in a dose-dependent manner (2012). 
Furthermore, significant interactions were observed between the 0.625 mg.kg lorcaserin dose and 
the 3.3 mg/kg dextromethorphan dose and between the 0.3125 mg/kg lorcaserin dose and the 10 
mg/kg dextromethorphan dose. While these results are exciting and warrant further investigation 
into a combination therapy of dextromethorphan and lorcaserin as a novel treatment for smoking 
cessation and nicotine addiction, first more work must be done to determine the relationship 
between these two drugs and why dose-dependent reductive interactions are not observed. Future 
research should also focus on the neurological foundations of interactions between glutamate 
antagonism and serotonin agonism in the reward pathway as suggested by the observed 
dextromethorphan-lorcaserin interactions.  
Future Interaction Studies 
 Looking forward, the results of these studies suggest that dextromethorphan, pyrilamine, 
and lorcaserin all have great promise for potential use in treating nicotine addiction. Future work 
should explore the interactions of pyrilamine and lorcaserin. Additional interaction studies 
should be conducted on dextromethorphan with a number of other agonists and antagonists to 
neurotransmitter molecules in the reward pathway and in related neurological systems. The 
nicotinic acetylcholine receptor antagonist mecamylamine (Zevin et al 2000) and alpha-4 beta-2 
partial agonist sazetidine-A have (Levin et al 2010) also been previously shown to significantly 
decrease nicotine self-administration independently, and are thus ideal candidates for future 
interaction studies.  
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